On Sept. 4, 2025 in Washington, HHS Secretary Robert F. Kennedy Jr. spent about three hours before the Senate Finance Committee defending recent CDC leadership changes and revised COVID-19 vaccine policies amid sharp questioning from both parties and continuing confusion about vaccine access.
Key Takeaways
- Kennedy defended the removal of CDC director Susan Monarez and subsequent staff departures, calling the moves necessary to address conflicts of interest and restore the agency.
- Monarez, in an op-ed, says she was pushed out for refusing to pre-approve vaccine recommendations; Kennedy denies that account.
- Republican and Democratic senators — including Bill Cassidy, Elizabeth Warren and Bernie Sanders — pressed Kennedy on staffing, funding and the new vaccine rules.
- Recent FDA changes narrowed COVID-19 vaccine authorizations to older, higher-risk groups, prompting inconsistent access across states and pharmacies.
- Large pharmacy chains report differing policies: CVS said it will provide shots in many states but requires prescriptions or is pausing service in others, creating short-term confusion for patients.
- Kennedy was notably combative during the hearing and declined at times to affirm widely cited COVID-19 mortality and vaccine impact figures.
Verified Facts
Susan Monarez served as CDC director for roughly one month before her removal; several senior CDC officials resigned in the days that followed in protest of the leadership changes. Monarez published an account in The Wall Street Journal asserting she was dismissed after refusing to sign off on vaccine recommendations prematurely.
At the Sept. 4 hearing, Sen. Ron Wyden directly asked whether Kennedy had told Monarez to “just go along” with recommendations; Kennedy denied that exchange. Other senators — including Elizabeth Warren and Bernie Sanders — pressed both the facts of that interaction and the broader rationale for the personnel moves.
Sen. Bill Cassidy highlighted policy shifts Kennedy has overseen, including rescinding roughly $500 million in federal mRNA vaccine funding and narrowing COVID-19 vaccine eligibility after recent FDA actions. Kennedy praised Operation Warp Speed historically but has since moved to limit vaccine availability to higher-risk groups.
Pharmacy chains and trade groups say the FDA’s authorization change will make access more complex for younger, otherwise healthy people: CVS reported it will continue offering COVID shots in 34 states, requires prescriptions in 13 states, and is holding off in New Mexico, Nevada and Massachusetts due to the changing regulatory environment; Walgreens said it will provide shots where legally permissible.
Context & Impact
The combined effect of rapid leadership turnover at CDC and tighter vaccine authorizations has two immediate impacts: heightened public confusion about who can get vaccinated and potential gaps in protection ahead of the winter respiratory season.
Legislative oversight appears likely to continue. Senators from both parties signaled interest in further hearings; Sen. Bernie Sanders said he would seek additional testimony from Monarez before relevant committees, and Sen. Bill Cassidy indicated continued oversight activity.
Longer term, the episode could affect public trust in federal health agencies. Repeated leadership reversals and visible clashes between HHS and career agency staff can undermine clear messaging on vaccine availability and the rationale for clinical guidance.
Official Statements
“These were absolutely necessary adjustments to restore the agency to its role as the world’s gold standard public health agency,”
HHS Secretary Robert F. Kennedy Jr.
“Dr. Monarez stands by what she said in The Wall Street Journal, would repeat it under oath and continues to support the vision she outlined at her confirmation hearing,”
Attorneys for Susan Monarez
Unconfirmed
- Whether Kennedy explicitly told Monarez to “just go along” with advisory committee recommendations remains disputed between the two parties and is a subject for further sworn testimony.
- Allegations that recently appointed CDC staffers uniformly have financial ties to vaccine skepticism or have been paid to testify against manufacturers require case-by-case verification.
- The near-term impact on vaccine uptake and hospitalization trends from these policy changes is expected but not yet measurable.
Bottom Line
The Sept. 4 hearing highlighted bipartisan concern about rapid personnel changes at CDC and the practical consequences of narrowing COVID-19 vaccine authorizations. For patients, the immediate effect is patchy access and uneven rules across states and pharmacies; for policymakers, it signals sustained scrutiny of HHS leadership decisions.
Expect additional oversight, possible witness subpoenas or follow-up hearings, and continuing debate about how to balance regulatory authority, clinical guidance, and public access to vaccines as winter approaches.